Opinion

Video

Treating a DME Patient Lost to Follow-Up with a Highly Durable Agent

Katherine Talcott, MD, presents the case of a patient with diabetic macular edema, and the rest of the panel share their clinical experiences and discuss factors that inform the utilization of more durable agents.

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
Vikas Chopra, MD, at AAO 2024: The role of MIGS in earlier intervention and safer techniques
AAO 2024: Weijie Violet Lin, MD, discusses risk factors for epithelium-off cross-linking
AAO 2024: Enhancing the paradigm of 'see one, do one, teach one' with technology
AAO 2024: Matt Giegengack, MD: Injectable endothelial cell therapy shows promise for improving vision and reducing glare in corneal edema
Related Content
CHMP issues positive opinion for the marketing authorization of FYB203, a biosimilar candidate to aflibercept
November 23rd 2024

CHMP issues positive opinion for the marketing authorization of FYB203, a biosimilar candidate to aflibercept

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Adverum Biotechnologies announces topline 52-week results from LUNA Phase 2 trial and 4-year OPTIC results
November 21st 2024

Adverum Biotechnologies announces topline 52-week results from LUNA Phase 2 trial and 4-year OPTIC results

Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

European Commission grants marketing authorization to aflibercept biosimilar from Sandoz Group
November 15th 2024

European Commission grants marketing authorization to aflibercept biosimilar from Sandoz Group

HuidaGene Therapeutics' IND application for HG202 for the treatment of nAMD cleared by FDA
November 12th 2024

HuidaGene Therapeutics' IND application for HG202 for the treatment of nAMD cleared by FDA

© 2024 MJH Life Sciences

All rights reserved.